Bio-Techne Announces Appointment Of Brenda Furlow As General Counsel

MINNEAPOLIS, Aug. 4, 2014 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) (d/b/a Bio-Techne), a leading global provider of life science reagents and clinical controls, announces the appointment of Brenda S. Furlow as Senior Vice President and General Counsel effective August 4, 2014. Ms. Furlow is a legal executive with experience in several globally diverse technology businesses, and has a broad understanding of the legal issues facing technology companies in today's complex legal environment.  Ms. Furlow will be responsible for legal and compliance matters for Bio-Techne and its affiliates.

Her recent experience includes several years as General Counsel of a publicly-traded medical devices company and, prior to that, almost ten years as General Counsel with Promega, a private life sciences company, both with worldwide operations. Ms. Furlow brings extensive experience in the areas of intellectual property, patent and licensing, compliance, litigation and regulatory. 

"We are very pleased to welcome Ms. Furlow to our executive team and company," said Charles Kummeth, President/CEO of Bio-Techne.  "Her background is perfectly aligned with our business and our strategic direction; her experience will be essential as we expand our global and platform footprint."

Ms. Furlow earned her Juris Doctor degree from the University of Chicago and a Bachelor of Arts from Calvin College.

Techne Corporation (d/b/a Bio-Techne), (NASDAQ: TECH), is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With over 24,000 products in its portfolio, Bio-Techne generated approximately $311 million in net sales in fiscal year 2013 and has over 1,000 employees worldwide. For more information on Bio-Techne and its brands, please visit

Forward Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the Company's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "may" or similar words. Forward-looking statements, including those relating to the Company's future business and strategic direction, involve risks and uncertainties that may affect actual results. The following important factors, among others, have affected and, in the future, could affect actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new biotechnology and clinical control products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

SOURCE Techne Corporation